Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4798-4810

  Rempel, Viktor ^a   Volz, Nicole ^b   Gläser, Franziska ^b   Nieger, Martin ^d   Bräse, Stefan ^b,c   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYBENZYL) 5 ISOPROPYL 8 METHYL 2H CHROMEN 2 ONE; 3 (2 METHOXYBENZYL) 5,8 DIMETHYL 2H CHROMEN 2 ONE; 3 (4 BROMOBENZYL) 5 METHOXY 7 PENTYL 2H CHROMEN 2 ONE; 3 (4 CHLOROBENZYL) 5 METHOXY 7 PENTYL 2H CHROMEN 2 ONE; 3 (4 FLUOROBENZYL) 5 METHOXY 7 PENTYL 2H CHROMEN 2 ONE; 3 (4 FLUOROBENZYL) 6 HYDROXY 5,7,8 TRIMETHYL 2H CHROMEN 2 ONE; 3 (4 FLUOROBENZYL) 6 METHOXY 5,7,8 TRIMETHYL 2H CHROMEN 2 ONE; 3 BENZYL 5 HYDROXY 2H CHROMEN 2 ONE; 3 BENZYL 5 METHOXY 2H CHROMEN 2 ONE; 3 BENZYL 6 HYDROXY 5,7,8 TRIMETHYL 2H CHROMEN 2 ONE; 3 BENZYL 6 METHOXY 5,7,8 TRIMETHYL 2H CHROMEN 2 ONE; 5 METHOXY 3 (4 METHOXY 3,5 DIMETHYLBENZYL) 7 PENTYL 2H CHROMEN 2 ONE; 6 HYDROXY 5,7,8 TRIMETHYL 3 (2 METHYLBENZYL) 2H CHROMEN 2 ONE; 6 METHOXY 3 (2 METHOXYBENZYL) 5,7,8 TRIMETHYL 2H CHROMEN 2 ONE; 6 METHOXY 5,7,8 TRIMETHYL 3 (2 METHYLBENZYL) 2H CHROMEN 2 ONE; 7 (1,1 DIMETHYLHEPTYL) 5 HYDROXY 3 (2 HYDROXYBENZYL) 2H CHROMEN 2 ONE; 7 (1,1 DIMETHYLOCTYL) 5 HYDROXY 3 (2 HYDROXYBENZYL) 2H CHROMEN 2 ONE; 8 (TERT BUTYL) 3 (2 METHOXYBENZYL) 5 METHYL 2H CHROMEN 2 ONE; ALKYL GROUP; CANNABINOID RECEPTOR; COUMARIN DERIVATIVE; G PROTEIN COUPLED RECEPTOR 55; LIGAND; MOLECULAR SCAFFOLD; RECEPTOR; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; NONHUMAN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; ANIMALS; CHO CELLS; COUMARINS; CRICETINAE; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879062913     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4005175     Document Type: Article

References (41)

1. Henstridge, C. M. Off-target cannabinoid effects mediated by GPR55 Pharmacology 2012, 89, 179-187
2. Schicho, R.; Storr, M. A potential role for GPR55 in gastrointestinal functions Curr. Opin. Pharmacol. 2012, 12, 653-658
3. Sharir, H.; Abood, M. E. Pharmacological characterization of GPR55, a putative cannabinoid receptor Pharmacol. Ther. 2010, 126, 301-313
4. Henstridge, C. M.; Balenga, N. A.; Kargl, J.; Andradas, C.; Brown, A. J.; Irving, A.; Sanchez, C.; Waldhoer, M. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55 Mol. Endocrinol. 2011, 25, 1835-1848
5. Obara, Y.; Ueno, S.; Yanagihata, Y.; Nakahata, N. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells PLoS One 2011, 6, e24284
6. 2 Pharmacol. Rev. 2010, 62, 588-631
7. Anavi-Goffer, S.; Baillie, G.; Irving, A. J.; Gertsch, J.; Greig, I. R.; Pertwee, R. G.; Ross, R. A. Modulation of l -alpha-lysophosphatidylinositol/ GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids J. Biol. Chem. 2012, 287, 91-104
8. Brown, A. J.; Daniels, D. A.; Kassim, M.; Brown, S.; Haslam, C. P.; Terrell, V. R.; Brown, J.; Nichols, P. L.; Staton, P. C.; Wise, A.; Dowell, S. J. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist J. Pharmacol. Exp. Ther. 2010, 337, 236-246
9. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Abood, M. E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands J. Biol. Chem. 2009, 284, 29817-29827
10. Zhao, P.; Abood, M. E. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors Life Sci. 2012, 92, 453-457
11. Balenga, N. A.; Aflaki, E.; Kargl, J.; Platzer, W.; Schröder, R.; Blättermann, S.; Kostenis, E.; Brown, A. J.; Heinemann, A.; Waldhoer, M. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils Cell Res. 2011, 21, 1452-1469
12. 2 partnership Cell Res. 2011, 21, 1391-1392
13. 1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55 J. Biol. Chem. 2012, 287, 44234-44248
14. Sharir, H.; Console-Bram, L.; Mundy, C.; Popoff, S. N.; Kapur, A.; Abood, M. E. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55 J. Neuroimmune Pharmacol. 2012, 7, 856-865
15. 2+ signaling and NFAT activation FASEB J. 2009, 23, 183-193
16. Okuno, T.; Yokomizo, T. What is the natural ligand of GPR55? J. Biochem. 2011, 149, 495-497
17. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl- sn -glycero-3-phosphoinositol: a possible natural ligand for GPR55 J. Biochem. 2009, 145, 13-20
18. Alexander, S. P. So what do we call GPR18 now? Br. J. Pharmacol. 2012, 165, 2411-2413
19. 9- Tetrahydrocannabinol and N -arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells Br. J. Pharmacol. 2012, 165, 2414-2424
20. McHugh, D.; Hu, S. S.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J. M.; Bradshaw, H. B. N -Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor BMC Neurosci. 2010, 11, 44-56
21. Henstridge, C. M.; Balenga, N. A.; Schröder, R.; Kargl, J. K.; Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J. L.; Kostenis, E.; Waldhoer, M.; Irving, A. J. GPR55 ligands promote receptor coupling to multiple signalling pathways Br. J. Pharmacol. 2010, 160, 604-614
22. Ross, R. A. l -alpha-Lysophosphatidylinositol meets GPR55: a deadly relationship Trends Pharmacol. Sci. 2011, 32, 265-269
23. Moreno-Navarrete, J. M.; Catalan, V.; Whyte, L.; Diaz-Arteaga, A.; Vazquez-Martinez, R.; Rotellar, F.; Guzman, R.; Gomez-Ambrosi, J.; Pulido, M. R.; Russell, W. R.; Imbernon, M.; Ross, R. A.; Malagon, M. M.; Dieguez, C.; Fernandez-Real, J. M.; Fruhbeck, G.; Nogueiras, R. The l -alpha- lysophosphatidylinositol/GPR55 system and its potential role in human obesity Diabetes 2012, 61, 281-291
24. Pineiro, R.; Maffucci, T.; Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation Oncogene 2011, 30, 142-152
25. Heynen-Genel, S.; Dahl, R.; Shi, S.; Milan, L.; Hariharan, S.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; Vicchiarelli, M.; Mangravita-Novo, A.; Smith, L. H.; Chung, T. D. Y.; Sharir, H.; Caron, M. G.; Barak, L. S.; Abood, M. E. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information (U.S.): Bethesda, MD, 2010; http://www.ncbi.nlm.nih.gov/books/NBK66153/.
26. Behrenswerth, A.; Volz, N.; Toräng, J.; Hinz, S.; Bräse, S.; Müller, C. E. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists Bioorg. Med. Chem. 2009, 17, 2842-2851
27. Rempel, V.; Volz, N.; Hinz, S.; Karcz, T.; Meliciani, I.; Nieger, M.; Wenzel, W.; Bräse, S.; Müller, C. E. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists J. Med. Chem. 2012, 55, 7967-7977
28. Toräng, J.; Vanderheiden, S.; Nieger, M.; Bräse, S. Synthesis of 3-alkylcoumarins from salicylaldehydes and α,β-unsaturated aldehydes utilizing nucleophilic carbenes: a new umpoled domino reaction Eur. J. Org. Chem. 2007, 6, 943-952
29. Jiang, Y.; Chen, W.; Lu, W. N-Heterocyclic carbene catalyzed conjugate umpolung reactions leading to coumarin derivatives RSC Adv. 2011, 2, 1540-1546
30. Jiang, Y.; Chen, W.; Lu, W. Synthesis of 3-arylcoumarins through N-heterocyclic carbene catalyzed condensation and annulation of 2-chloro-2-arylacetaldehydes with salicylaldehydes Tetrahedron 2013, 69, 3669-3676
31. van der Lee, M. M.; Blomenrohr, M.; van der Doelen, A. A.; Wat, J. W.; Smits, N.; Hanson, B. J.; van Koppen, C. J.; Zaman, G. J. Pharmacological characterization of receptor redistribution and beta-arrestin recruitment assays for the cannabinoid receptor 1 J. Biomol. Screening 2009, 14, 811-823
32. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 2007, 152, 1092-1101 (Pubitemid 350166046)
33. 2 receptors and blockade of the related GPR55 ACS Med. Chem. Lett. 2013, 4, 41-45
34. Müller, C. E.; Schiedel, A. C.; Baqi, Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development Pharmacol. Ther. 2012, 135, 292-315
35. Milligan, G.; Smith, N. J. Allosteric modulation of heterodimeric G-protein-coupled receptors Trends Pharmacol. Sci. 2007, 28, 615-620 (Pubitemid 350166577)
36. Kenakin, T. P. Allosteric Drug Antagonism. In A Pharmacology Primer, 3 rd ed.; Kenakin, T. P., Eds.; Elsevier Academis Press: London, 2009; pp 138-139.
37. Southern, C.; Cook, J. M.; Neetoo-Isseljee, Z.; Taylor, D. L.; Kettleborough, C. A.; Merritt, A.; Bassoni, D. L.; Raab, W. J.; Quinn, E.; Wehrman, T. S.; Davenport, A. P.; Brown, A. J.; Green, A.; Wigglesworth, M. J.; Rees, S. Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors J. Biomol. Screening 2013, 18, 599-609
38. Rahn, E. J.; Hohmann, A. G. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside Neurotherapeutics 2009, 6, 713-737
39. 2 cannabinoid receptor ligands: structural investigations around a novel class of full agonists J. Med. Chem. 2012, 55, 6608-6623
40. Pertwee, R. G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids AAPS J. 2005, 7, E625-654
41. Sheldrick, G. M. A short history of SHELX Acta Crystallogr. 2008, 64, 112-122